Royal London Asset Management Ltd. Increases Stock Holdings in DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

Royal London Asset Management Ltd. grew its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 8.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 96,106 shares of the medical instruments supplier’s stock after purchasing an additional 7,381 shares during the period. Royal London Asset Management Ltd.’s holdings in DENTSPLY SIRONA were worth $3,420,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Bar Harbor Wealth Management acquired a new stake in DENTSPLY SIRONA in the 4th quarter valued at about $4,931,000. DAVENPORT & Co LLC purchased a new position in DENTSPLY SIRONA in the fourth quarter worth approximately $1,220,000. Dimensional Fund Advisors LP grew its holdings in DENTSPLY SIRONA by 10.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,122,355 shares of the medical instruments supplier’s stock worth $75,535,000 after acquiring an additional 197,431 shares in the last quarter. Power Corp of Canada purchased a new stake in shares of DENTSPLY SIRONA in the 4th quarter valued at approximately $4,380,000. Finally, Generation Investment Management LLP raised its holdings in shares of DENTSPLY SIRONA by 43.4% in the 4th quarter. Generation Investment Management LLP now owns 6,598,211 shares of the medical instruments supplier’s stock valued at $234,830,000 after purchasing an additional 1,998,012 shares in the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

DENTSPLY SIRONA Stock Performance

NASDAQ:XRAY traded down $0.59 during trading hours on Friday, reaching $26.11. 1,758,606 shares of the company’s stock were exchanged, compared to its average volume of 2,148,063. DENTSPLY SIRONA Inc. has a 1-year low of $25.83 and a 1-year high of $41.65. The company has a quick ratio of 0.97, a current ratio of 1.43 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $5.42 billion, a price-to-earnings ratio of -59.34, a P/E/G ratio of 1.16 and a beta of 1.04. The company has a 50-day moving average of $28.92 and a 200 day moving average of $32.19.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.42 earnings per share for the quarter, hitting the consensus estimate of $0.42. The business had revenue of $953.00 million during the quarter, compared to the consensus estimate of $969.45 million. DENTSPLY SIRONA had a negative net margin of 2.41% and a positive return on equity of 11.54%. The business’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.39 earnings per share. Research analysts anticipate that DENTSPLY SIRONA Inc. will post 2.03 EPS for the current year.

DENTSPLY SIRONA Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 12th. Stockholders of record on Friday, June 28th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 2.45%. The ex-dividend date of this dividend is Friday, June 28th. DENTSPLY SIRONA’s payout ratio is currently -145.45%.

Analyst Ratings Changes

XRAY has been the topic of several recent analyst reports. Robert W. Baird dropped their target price on DENTSPLY SIRONA from $35.00 to $33.00 and set a “neutral” rating on the stock in a report on Friday, May 3rd. Needham & Company LLC cut their target price on DENTSPLY SIRONA from $42.00 to $36.00 and set a “buy” rating on the stock in a research report on Friday, May 3rd. StockNews.com downgraded DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Piper Sandler reissued a “neutral” rating and set a $32.00 price objective (down previously from $35.00) on shares of DENTSPLY SIRONA in a report on Friday, May 3rd. Finally, Leerink Partnrs restated an “outperform” rating on shares of DENTSPLY SIRONA in a report on Monday, February 26th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $35.22.

Insider Transactions at DENTSPLY SIRONA

In other news, Director Gregory T. Lucier bought 3,577 shares of DENTSPLY SIRONA stock in a transaction dated Friday, May 31st. The stock was bought at an average price of $27.95 per share, for a total transaction of $99,977.15. Following the purchase, the director now owns 58,374 shares of the company’s stock, valued at $1,631,553.30. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.52% of the company’s stock.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.